Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam

Huyen Thi Phung 1,2, Minh Cong Truong 3*, Long Thanh Nguyen 3, Anh Thi Van Dang 4, Thanh Ha Vu 5, Hoa Thi Nguyen 1

Abstract

Objective: This study aimed to analyze the treatment outcome and toxicities, along with prognosis factors of patients with FIGO 2018 stage III cervical cancer treated with definitive concurrent chemoradiation. Methods: A total of 83 stage III cervical cancer patients with good performance status (ECOG PS 0, 1) were treated with three-dimensional conformal radiation therapy (3D-CRT) combined with chemotherapy (weekly cisplatin), followed by high-dose-rate (HDR) brachytherapy between January 2017 and March 2019 at Vietnam National Cancer hospital. Treatment outcomes and prognosis factors were assessed along with acute and late toxicities. Results: The 3-year DFS was 67.8% and 3-year OS was 80.3%. On multivariate analyses, short axis of pelvic lymph node diameter of ≥ 15mm, invasion of the lower third of vagina and para-aortic lymph node metastasis were identified as adverse prognostic factors for DFS. The cumulative incidence rate of gastrointestinal and genitourinary toxicity (≥ grade 2) at the 3-year follow-up were 29.6% and 11.6%, respectively. Conclusions: 3D CRT and HDR brachytherapy with concurrent chemotherapy is an effective treatment, with acceptable toxicity for FIGO 2018 stage III cervical cancer in Vietnam.

Keywords: Cervical cancer- stage III- 3D CRT- 3-year DFS- late toxicity

Introduction

Cervical cancer has still been one of the most common cancers globally, especially in developing countries where HPV vaccination has not been widely implemented (Bray et al., 2013). According to GLOBOCAN 2018, cervical cancer ranked fourth in both incidence and mortality rates among female cancers, with about 8.6 million new cases and 4.2 million deaths each year (Bray et al., 2018). In countries with low-middle Human Development Index, cervical cancer is the second most common cause of malignancy-related mortality and morbidity, and more than 70% patients presented at advanced stages of disease (Gargiulo et al., 2016). In Vietnam, the lack of routine population-based screening and HPV vaccination leads to the majority of patients being diagnosed with locally advanced cervical cancer (Pham et al., 2019).

Currently, early cervical cancer (FIGO stage IA1-IIA1) is usually treated with surgery, but concurrent chemoradiation is the standard of care for locally advanced cases (FIGO stage IB2-IVA). Since early 2000s, American National Cancer Institute has published multiple large-scale randomized clinical trials showing that concurrent chemoradiation reduced the recurrence rate and improved survival compared to radiotherapy alone in locally advanced cervical (Keys et al., 1999; Morris et al., 1999; Rose et al., 1999; Whitney et al., 1999; Peters et al., 2000).

In 2018, The International Federation of Gynecology and Obstetrics (FIGO) revised their 2014 staging system with significant changes as regional nodal metastasis (pelvic and para-aortic lymph nodes) was classified as stage IIIC regardless of tumor diameter and invasion into surrounding structures (except for bladder and rectum) (Bhatla et al., 2019). As a result, stage III has become the most heterogenous stage, and factors for further risk stratification and prognosis of this stage should be identified (Liu et al., 2019; Grigsby et al., 2020). Besides, to our best knowledge, data on treatment outcome and toxicities in patients with stage III cervical cancer according to the new FIGO system is limited, especially in Asian population (Liu et al., 2020; Raut et al., 2020).

In the present study, we aim to analyze the treatment outcome and toxicities, along with prognosis factors of stage III cervical cancer in Vietnam.
Vietnamese patients with FIGO 2018 stage III cervical cancer treated with definitive concurrent chemoradiation.

Materials and Methods

Study design

This was a retrospective cohort study of patients with stage III cervical cancer treated at Vietnam National Cancer Hospital. Our institution is a referral oncology center for Northern Vietnam and is among few centers that provide radiotherapy for cervical cancer in the country. Convenience sampling method was used to enroll patients admitted from January 2017 to March 2019. The protocol of this study was approved by the human research ethics committee at Vietnam National Cancer Hospital.

Study population

Inclusion and exclusion criteria

The eligibility criteria included cervical cancer diagnosed by histopathology of biopsy specimen; treated with definitive concurrent chemoradiation; an Eastern Cooperative Oncology Group performance status score less than 2; and whose medical records and radiation data were available to the investigators. The stage was assigned in accordance with the 2018 FIGO Staging System for Uterine Cervical Cancer (Bhatla et al., 2019). Pelvic/para-aortic lymph nodes involvement was defined as one of the following: (1) having FDG accumulation greater than liver accumulation or standard uptake value (SUV) > 2.5 ng/ml on positron emission tomography/computed tomography (PET/CT), or (2) the short axis diameter ≥ 10mm on pelvic magnetic resonance imaging (MRI) or CT (Liu et al., 2019). We excluded patients who underwent palliative RT only or previous treatment for cervical cancer, those who received preoperative chemoradiation followed by surgery, those with neuroendocrine carcinoma of the cervix and patients who did not had either abdominopelvic CT scan or pelvic MRI for lymph node assessment.

Data collection

We retrospectively reviewed medical reports of patients treated with concurrent chemoradiation at our institution during the study period. Patients assessed as stage III cervical cancer according to the former FIGO 2014 staging system and those with pelvic/para-aortic lymph node metastasis on imaging that satisfied study criteria were selected. Data on patients’ demographic, tumor, lymph nodes characteristics and toxicities along with disease free survival (DFS) and overall survival (OS) was recorded.

Treatment Protocol and Follow-Up

Radiation therapy

The patients were treated with three-dimensional conformal radiation therapy (3D CRT) combined with chemotherapy, followed by high-dose-rate (HDR) brachytherapy. The clinical target volume (CTV) included the gross tumor volume (GTV), cervix, entire uterus, parametrium and upper part of the vagina to 3 cm below the most inferior extent of tumor. The CTV-node included the common, external, and internal iliac and presacral lymph nodes and/or para-aortic lymph nodes with a 7 mm margin around the vessels and any additional visible lymph nodes. The planning target volume (PTV) was created by expanding the CTV with a 10 mm margin and an additional 5 mm margin to the cervix and uterus. Patients were then treated with anterior (AP), posterior (PA) and lateral conformal fields with daily dose of 1.8 Gy - 2 Gy to a total dose of 45-50.4 Gy. Bladder and rectal blocks after 36-40Gy and an additional boost to the parametrium or metastatic lymph nodes to 59-61 Gy were given at the discretion of the treating physician.

A dose of 30-36 Gy in 3-5 fractions was delivered to point A in patients receiving 2D brachytherapy according to International Commission of Radiation Units (ICRU) 38. For patients who underwent 3D brachytherapy, at least 90% of the high-risk CTV received a dose of 30-36 Gy in 3-5 fractions.

Chemotherapy

The standard chemotherapy regimen was weekly cisplatin (40 mg/m²) for 5 cycles during the external beam phase of the radiation therapy. Chemotherapy and radiation therapy were started simultaneously.

Toxicities

The early and late toxicities were assessed during treatment and at each 2-3 month-follow-up according to RTOG/EORTC (Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer) scale (Cox, 1995).

Data analysis

Data was analysed using IBM SPSS Statistics for Windows version 26.0 (IBM Corp., Armonk, NY). Depending on the distribution, continuous data were presented as mean±standard deviation or median (interquartile range (IQR)) and categorical data as number (percentage). Comparison was done using the Fisher’s exact test and Chi-squared tests as appropriated. OS and DFS were estimated by the Kaplan–Meier method and compared by the log-rank test. Stepwise forward direction selection strategy was used to identify parameters for multivariate Cox proportional hazard regression models to evaluate factors associated with DFS. Factors and cut-off selected in the survival analysis were selected based on literature review (Song et al., 2013; Liu et al., 2019). All tests were two-tailed and differences were considered statistically significant at p values <0.05.

Results

Patients characteristics

A total of 83 patients with stage III cervical cancer were treated with definitive concurrent chemoradiation in our institution from January 2017 to March 2019. The study population had a median age of 55 (IQR 46-61), most of which had squamous cell carcinoma (92.8%). The mean tumor diameter was 50.8±15.8 mm. Details on tumor invasion and nodal metastasis were presented in Table 1. Most patients had stage IIB or IIIC1 according to FIGO 2018 classification due to pelvic wall invasion and pelvic
lymph node metastasis (34.9% and 60.2% respectively).

Nearly all patients (99%) completed the treatment, in which the majority had an A point dose of 80-90Gy and received ≥4 cisplatin cycles (accounting for 68.7% and 80.7% respectively). Almost half of the cases finished treatment within 8 weeks. Beside 3 patients with para-aortic lymph node metastasis, 13 other patients who were considered high risk for para-aortic lymph node metastasis by treating clinician also received extended-field radiotherapy.

**Outcome and pattern of recurrence**

The median duration of follow up was 29.6 months (range 4.0 – 44.5 months), disease recurrence or death was recorded in 23 (27.7%) patients. The 3-year DFS was 67.8% and 3-year OS was 80.3%. The 3-year DFS for stage IIIB and IIIC1 were 70.8% and 69.7%

### Table 1. Patient Demographics, Clinical and Imaging Characteristics

| Characteristic                          | No. of patients (%) | N=83 |
|-----------------------------------------|---------------------|------|
| Age (median (IQR))                      | 55 (46-61)          |      |
| Histology                               |                     |      |
| SCC                                     | 77 (92.8%)          |      |
| Adenocarcinoma                          | 6 (7.2%)            |      |
| Tumor size                              |                     |      |
| ≤ 40mm                                  | 23 (27.7%)          |      |
| > 40mm                                  | 60 (72.3%)          |      |
| Vaginal involvement                     |                     |      |
| No involvement                          | 3 (3.6%)            |      |
| Upper third                             | 57 (68.7%)          |      |
| Middle third                            | 13 (15.7%)          |      |
| Lower third                             | 10 (12.0%)          |      |
| Parametrial infiltration                |                     |      |
| No involvement                          | 13 (15.7%)          |      |
| Unilateral                              | 19 (22.9%)          |      |
| Bilateral                               | 51 (61.4%)          |      |
| Invasion of pelvic wall                 |                     |      |
| No                                      | 40 (48.2%)          |      |
| Yes                                     | 43 (51.8%)          |      |
| Pelvic lymph node metastasis            |                     |      |
| No                                      | 29 (34.9%)          |      |
| Unilateral                              | 28 (33.7%)          |      |
| Bilateral                               | 26 (31.3%)          |      |
| Short axis diameter of pelvic lymph nodes |                 |      |
| < 15mm                                  | 65 (78.3%)          |      |
| ≥ 15mm                                  | 18 (21.7%)          |      |
| Para-aortic lymph node metastasis       |                     |      |
| No                                      | 80 (96.4%)          |      |
| Yes                                     | 3 (3.6%)            |      |
| Stage (FIGO 2018)                       |                     |      |
| IIIA                                     | 1 (1.2%)            |      |
| IIIB                                     | 29 (34.9%)          |      |
| IIIC1                                    | 50 (60.2%)          |      |
| IIIC2                                    | 3 (3.6%)            |      |

### Table 2. Radiotherapy and Chemotherapy Treatment Characteristics

| Characteristic                          | No. of patients (%) | N=83 |
|-----------------------------------------|---------------------|------|
| Extended field radiotherapy (EFRT)      |                     |      |
| Yes                                     | 16 (19.3%)          |      |
| No                                      | 67 (80.7%)          |      |
| Total A point dose                      |                     |      |
| < 80 Gy                                 | 19 (22.9%)          |      |
| 80-90 Gy                                | 57 (68.7%)          |      |
| > 90 Gy                                 | 7 (8.4%)            |      |
| Completion of radiotherapy              |                     |      |
| Yes                                     | 82 (98.8%)          |      |
| No                                      | 1 (1.2%)            |      |
| Duration of radiotherapy                |                     |      |
| ≤8 weeks                                | 41 (49.4%)          |      |
| >8 weeks                                | 42 (50.6%)          |      |
| Concurrent chemotherapy                 |                     |      |
| 1-3 cycles                              | 16 (19.3%)          |      |
| ≥4 cycles                               | 67 (80.7%)          |      |

Figure 1. Kaplan–Meier Curve of Disease-Free Survival (DFS) and Overall Survival (OS) of Study Population.
respectively. Univariate analysis results indicated that lower third vaginal involvement, short axis diameter of pelvic nodes ≥ 15 mm, para-aortic lymph node metastasis and total treatment duration > 8 weeks were associated with disease recurrence. Meanwhile, multivariate analysis with stepwise approach only identified the former three features were significant prognostic factors for recurrence (see Table 3 for details).

Among cases with recurrence at primary tumor site, 6/7 patients had bulky tumor (> 4 cm in diameter) and 3/7 patients had lower third vaginal involvement. Meanwhile, 3/6 pelvic node recurrences had short axis diameter of pelvic nodes ≥ 15 mm at presentation. There were 3 cases with para-aortic recurrence, two of which were in-field of EFRT radiotherapy treatment.

### Toxicities

The numbers of patients with acute and late toxicities from chemoradiation treatment were presented in Table 5. During treatment, 31 (37.3%) patients had neutropenia.

### Table 3. Factors Associated with 3-Year Disease-Free Survival (DFS) in Univariate and Multivariate Cox Proportional Hazards Model

| Factors                              | N=83 (%) | 3-year DFS | Univariate analysis | Multivariate analysis |
|--------------------------------------|----------|------------|---------------------|-----------------------|
|                                      |          |            | p                   | HR (95% CI)*           | p                     |
| Histology                            |          |            |                     |                       |
| SCC                                  | 77       | 68.00%     | 0.749               | -                     |
| AC                                   | 6        | 62.50%     | -                   | -                     |
| Tumor size                           |          |            |                     |                       |
| ≤ 40mm                                | 23       | 81.80%     | 0.016               | -                     |
| > 40mm                                | 60       | 63.00%     | -                   | -                     |
| Lower third vaginal involvement      |          |            |                     |                       |
| No                                   | 73       | 74.10%     | <0.001              | 12.373                | 4.399-34.806          |
| Yes                                  | 10       | 17.50%     | -                   | -                     |
| Parametrial infiltration             |          |            |                     |                       |
| No                                   | 13       | 76.20%     | 0.746               | -                     |
| Yes                                  | 70       | 67.10%     | -                   | -                     |
| Pelvic wall invasion                 |          |            |                     |                       |
| No                                   | 40       | 73.20%     | 0.501               | -                     |
| Yes                                  | 43       | 63.20%     | -                   | -                     |
| Bilateral nodal metastasis           |          |            |                     |                       |
| No                                   | 57       | 72.10%     | 0.182               | -                     |
| Yes                                  | 26       | 53.80%     | -                   | -                     |
| Short axis diameter of pelvic nodes  |          |            |                     |                       |
| < 15mm                                | 65       | 74.00%     | 0.008               | 4.07                  | 1.666-9.943           |
| ≥ 15mm                                | 18       | 45.80%     | -                   | -                     |
| Para-aortic lymph node metastasis   |          |            |                     |                       |
| No                                   | 80       | 70.40%     | <0.001              | 21.095                | 5.357-83.068          |
| Yes                                  | 3        | 0%         | -                   | -                     |
| Treatment duration                   |          |            |                     |                       |
| ≤8 weeks                             | 41       | 84.90%     | 0.017               | -                     |
| >8 weeks                             | 42       | 55.80%     | -                   | -                     |

*, Hazard ratio of recurrence

### Table 4. Pattern of Relapse after Definitive Concurrent Chemoradiation*

| Stage | Pelvic | Para-aortic | Distant | Unknown** |
|-------|--------|-------------|---------|-----------|
|       | Central| Nodal       |         |           |
| IIIA  | -      | -           | -       | -         |
| IIIB  | 5      | 2           | 1       | 4         |
| IIIC1 | 2      | 4           | 2       | 5         |
| IIIC2 | -      | -           | -       | -         |
| Total | 7      | 6           | 3       | 9         |

*, More than one sites of relapse could be recorded in one patient; **, Death without any documented recurrence sites.
and 4 (4.8%) patients had thrombocytopenia. Grade 3-4 hematological toxicities were recorded in 7 (8.4%) cases. The cumulative incidence rate of gastrointestinal and genitourinary toxicity (≥ grade 2) at the 3-year follow-up was 29.6% and 11.6%, respectively.

**Discussion**

Since the introduction of the new FIGO classification in 2018, there have been significant changes in cervical cancer staging in clinical practice and stage III has been more commonly encountered at disease presentation. In a retrospective validation study on 1,282 patients from 1997 to 2019, while FIGO 2018 had better survival discriminatory ability compared to FIGO 2009, survival of stage III subclasses were heterogeneous (Grigsby et al., 2020). 5-year DFS of stage IIIA, IIIB, IIC1 and IIC2 were 46%, 55%, 62%, 35% respectively, in which the prognosis of patients with stage IIC1 was even better than those with stage IIIB (Grigsby et al., 2020). In our study, most patients had FIGO 2018 stage IIIB or IIC1 (accounted for 34.9% and 60% respectively), both groups had approximately equal 3-year DFS of about 70%. However, one should note that 24% of our patients with stage IIC1 had T3b disease (pelvic wall invasion), which might contribute to the attenuated difference between the two subgroups. Another validation study on Asian cohort reported similar 3-year DFS rates of 70.4% for IIIB and 66.3% for stage IIC1 (Liu et al., 2020). Compared to stage IIC1, stage IIC2 had significantly poorer outcomes. In an analysis of 17,173 patients based on National Cancer Database, para-aortic lymph node metastasis was associated with a hazard ratio 2.14, p<0.001 for overall survival in multivariate analysis, with 5-year OS of only 39.4% (McComas et al., 2020). In our study, all three patients with stage IIC2 have died, in which the longest survival was 19 months.

A large-scaled analysis of The Surveillance, Epidemiology, and End Results Program data on 11,733 patients with stage III cervical cancer showed that 5-year cause-specific survival of stage IIC1 was significantly associated with T stage (74.8% for T1, 58.7% for T2, and 39.3% for T3) (Matsuo et al., 2019). Therefore, besides FIGO stage, the detail extent of tumor invasion also plays an important role in disease prognosis and might provide further risk stratification. In our study, lower third vaginal involvement (LTI) was an independent risk factor for disease recurrence in multivariate regression, regardless of nodal involvement and pelvic wall invasion. In a retrospective matched analysis of 216 patients with stage IIIB cervical cancer, LTI was associated with inferior PFS and OS, with hazard ratios of 1.64 (95%CI 1.12–2.41) and 1.63 (95%CI 1.11–2.40) respectively (Katanyoo, 2017). In this study, patients with LTI had higher risk of local progression but not distant metastasis, probably due to inadequate local treatment since the lower part of the vagina might not be fully reached by brachytherapy.

Beside LTI, large nodal disease (short axis diameter of pelvic lymph nodes ≥ 15mm) and para-aortic lymph node metastasis were also associated with recurrence in our cohort. In the group with large nodal metastasis, 9/18 patients recur (5.07 times higher chances compared to those without), in which 5/9 cases developed recurrent pelvic/para-aortic nodes. The impact of not only the presence of lymph node metastasis but also the characteristics of the nodes on survival for patients with cervical cancer has been investigated in several studies (Narayan et al., 2009; Song et al., 2013; Li et al., 2016). Song et al reported that the 5-year DFS for patients with negative lymph node, lymph node diameter <15 mm and lymph node diameter ≥15 mm were 80%, 67% and 50%, respectively (P < 0.001) (Song et al., 2013). The size of lymph node also significantly affected survival in a study of Li et, in which the 3-year OS of patients with lymph node ≥15mm in size was 72.1%, significantly lower than 87.1% in patients with lymph node <15mm (Li et al., 2016). Moreover, the number and volume of pelvic lymph node metastasis, matted/necrotic lymph nodes were also associated with survival in patients with cervical cancer (Li et al., 2016; Liu et al., 2019).

In patients with high-risk lymph node characteristics, lymph node–directed simultaneous integrated boost with intensity-modulated radiation therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT) might be beneficial to improve locoregional control with acceptable rates of adverse events (Jethwa et al., 2018). Our study employed 3D conformal radiation therapy, which did not facilitate simultaneous lymph node boost and the in-field lymph node recurrence rate was considerably high in patients with large pelvic node metastasis. In a developing country like Vietnam, inadequate insurance coverage and waiting list issue due to shortage of modern radiotherapy facilities might put the use of IMRT/VMAT for cervical cancer under careful consideration. In a recent report of International Atomic Energy Agency (IAEA), out of pocket health expenditure was considerably high in Southeast Asia, accounting for 53.95%, 40.47% and 55.42% of total health expenditure in Philippines, Malaysia and Singapore respectively, whereas a significant proportion of radiotherapy services are owned by private sector in these countries (Rosenblatt and Zubizarreta, 2017). The results of this study can help physician to identify the subgroup of patients who may have more benefits from modern and more expensive radiation therapy techniques. Apart from simultaneous boost, extended-field irradiation therapy (EFRT) should also be considered in patients with lymph node diameter ≥15 mm, according to a recent report of Wang et al (Wang et al., 2019). Adding more chemotherapy is an alternative approach of escalated treatment for high risk patients. A phase III study comparing cisplatin plus gemcitabine during concurrent RT plus two adjuvant cycles of cisplatin-gemcitabine with cisplatin alone for patients with locally advanced cervical cancer demonstrated improvement in DFS and OS but was associated with significantly more serious (grade 3/4) toxicities (Dueñas-González et al., 2011). We are still awaiting the results of some ongoing trials such as OUTBACK (ClinicalTrials.gov identifier: NCT01414608) and INTERLACE (ClinicalTrials.gov identifier: NCT01566240) trials which investigate adjuvant and neoadjuvant taxane-platinum chemotherapy added to concurrent chemoradiation. These trials will...
provide further evidence for the escalated chemotherapy treatment and might bring new therapeutic options for high-risk cervical cancer.

As discussed above, the presence of locoregional nodal disease is an important prognosis factor and might play a role in treatment planning. Pre-treatment nodal evaluation by abdominopelvic CT scan in locally advanced cervical cancer is necessary even in developing countries, as it could help to avoid unnecessary surgery and might be cost-effective (Haldorsen et al., 2019). However, there is still some debates in the size threshold to define lymph node positivity on imaging, and the most widely criterion is the short axis diameter ≥ 10 mm (Huang and Fang, 2018). Although smaller lymph node might harbor metastatic tumor, a previous study suggested that failure in pelvic lymph nodes is rare in cases with nodes smaller than 10 mm in short diameter (Song et al., 2013).

In our study, a treatment duration over 56 days also influenced treatment outcome in univariate analysis for DFS. Several studies have recorded that treatment time exceeding 8 weeks and nonoptimal RT had poorer survival (Diaz et al., 2014; Ohri et al., 2016). However, in the stepwise multivariate analysis, treatment time longer than 8 weeks was not significantly associated with inferior outcome, probably because most patients with treatment time over 56 days had more fractions of brachytherapy rather than RT noncompliance, similar to the findings of Katanyoo (Katanyoo, 2017).

In terms of toxicities, the 3-year cumulative incidence rates of gastrointestinal (GI) and genitourinary (GU) toxicity (≥ grade 2) were 29.6% and 11.6%, respectively. Late GI and GU toxicities of grade 3, 4 included rectal bleeding that required surgery (7 cases), rectovaginal fistula (1 case), small bowel obstruction (1 case) and hematuria requiring cystoscopy (2 cases). Our rates are comparable to the data reported in a systematic review of 19 trials of concurrent chemoradiation with 3D-CRT (Kirwan et al., 2003). In which, the rates of grade 1-2 and 3-4 of GI and GU toxicities were 45.2%, 17.5%, 8%, 1.5% respectively (Kirwan et al., 2003). Chronic toxicities were considerably lower in a recent report in China in which IMRT was utilized in the majority of patients (Wang et al., 2017). Several studies have shown benefits of IMRT/VMAT in terms of reduction in dose to organs at-risk and toxicities (Yahya et al., 2015; Lei et al., 2019). However, further studies are required to robustly confirm the superiority of IMRT/VMAT over 3D-CRT for cervical cancer.

Our study has some limitations: the study is a retrospective single institution analysis, with small sample size and convenience sampling method. Besides, since we only included patients who had abdominopelvic CT scan or pelvic MRI for lymph node assessment, our study is subjected to selection bias. Moreover, due to its retrospective nature, more detailed information such as number and location (common versus external/internal iliac) lymph nodes could not be fully recorded.

In conclusion, 3D CRT and HDR brachytherapy with concurrent chemotherapy is an effective treatment, with acceptable toxicity, for FIGO 2018 stage III cervical cancer in Vietnam. Escalated treatment for high-risk patients such as those with short axis of pelvic lymph node diameter of ≥ 15 mm, invasion of the lower third of vagina and para-aortic lymph node metastasis should be evaluated in further studies.

Author Contribution Statement

Conception and design: Phung Thi Huyen, Truong Cong Minh, Nguyen Thanh Long. Administrative support: Phung Thi Huyen, Nguyen Thi Hoa. Collection and assembly of data: Phung Thi Huyen, Truong Cong Minh, Nguyen Thanh Long, Dang Thi Van Anh, Vu Ha Thanh. Data analysis and interpretation: Phung Thi Huyen, Truong Cong Minh, Nguyen Thanh Long, Nguyen Thi Hoa. Manuscript writing: All authors. Final approval of manuscript: All authors. Accountable for all aspects of the work: All authors.

Acknowledgements

Ethics considerations

This study was approved by the ethics committee of the Vietnam National Cancer Institute. Informed consent was waived due to the retrospective nature of this study.

Declaration of Conflicting Interests

The Authors declare that there is no conflict of interest.

References

Bhatla N, Berek JS, Freedes MC, et al (2019). Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynecol Obstet, 145, 129-35.

Bray F, Ferlay J, Soerjomataram I, et al (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394-424.

Bray F, Ren JS, Masuyer E, et al (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer, 132, 1133-45.

Cox JD (1995). Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys, 31, 1341-6.

Diaz J, Yu D, Micaliy B, et al (2014). Radiation therapy with concurrent chemotherapy for locally advanced cervical carcinoma: outcome analysis with emphasis on the impact of treatment duration on outcome. Obstet Gynecol Int, 2014.

Dueñas-González A, Zarbá JJ, Patel F, et al (2011). Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIIB to IVA carcinoma of the cervix. J Clin Oncol, 29, 1678-85.

Gargiulo P, Arenare L, Pisano C, et al (2016). Long-term toxicity and quality of life in patients treated for locally advanced cervical cancer. Oncology, 90, 29-35.

Grigsby PW, Massad LS, Mutch DG, et al (2020). FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Gynecol Oncol, 157, 639-43.

Haldorsen IS, Lura N, Blaakær J, et al (2019). What is the role of imaging at primary diagnostic work-up in uterine cervical cancer?. Curr Oncol Rep, 21, 1-15.

Huang B-x, Fang F (2018). Progress in the study of lymph...
node metastasis in early-stage cervical cancer. *Curr Med Sci*, 38, 567-74.

Jethwa KR, Jang S, Gonuguntla K, et al (2018). Lymph node-directed simultaneous integrated boost in patients with clinically lymph node–positive cervical cancer treated with definitive chemoradiotherapy: clinical outcomes and toxicity. *J Radiat Oncol*, 2018, 1-9.

Katsanevakis GP (2017). Comparing treatment outcomes of stage IIB cervical cancer patients between those with and without lower third of vaginal invasion. *J Gynecol Oncol*, 28.

Keys HM, Bundy BN, Stehman FB, et al (1999). Cisplatin, radiation, and adjutant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med*, 340, 1154-61.

Kirwan JM, Symonds P, Green JA, et al (2003). A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. *Radiother Oncol*, 68, 217-26.

Lei C, Ma S, Huang M, et al (2019). Long-term survival and late toxicity associated with pelvic lymph node metastasis in early-stage cervical cancer patients. *Front Oncol*, 9, 520.

Li X, Wei L-C, Zhang Y, et al (2016). The prognosis and risk stratification based on pelvic lymph node characteristics in patients with locally advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. *Int J Gynecol Cancer*, 26.

Liu X, Hou X, Hu K, et al (2019). A risk stratification for patients with cervical cancer in stage IIIC1 of the 2018 FIGO staging system treated with definitive chemoradiotherapy. *Int J Radiat Oncol Biol Phys*, 105, E327.

Liu X, Wang J, Hu K, et al (2020). Validation of the 2018 FIGO staging system of cervical cancer for stage III patients with a cohort from China. *Cancer Manage Res*, 12, 1405.

Matsuo K, Machida H, Mandelbaum RS, et al (2019). Validation of the 2018 FIGO cervical cancer staging system. *Gynecol Oncol*, 152, 87-93.

McComas KN, Torgeson AM, Ager BJ, et al (2020). The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. *Gynecol Oncol*, 156, 85-92.

Morris M, Eifel PJ, Lu J, et al (1999). Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N Engl J Med*, 340, 1137-43.

Narayan K, Fisher RJ, Bernshaw D, et al (2009). Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent. *Int J Gynecol Cancer*, 19.

Ohri N, Rapkin BD, Guha C, et al (2016). Radiation therapy noncompliance and clinical outcomes in an urban academic cancer center. *Int J Radiat Oncol Biol Phys*, 95, 563-70.

Peters III WA, Liu P, Barrett RJ, et al (2000). Concurrent chemoradiotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *Obstet Gynecol Surv*, 55, 491-2.

Pham T, Bui L, Kim G, et al (2019). Cancers in Vietnam—burden and control efforts: a narrative scoping review. *Cancer Control*, 26, 1073274819863802.

Raut A, Chopra S, Mittal P, et al (2020). FIGO classification 2018: validation study in patients with locally advanced cervix cancer treated with chemoradiation. *Int J Radiat Oncol Biol Phys*, 108, 1248-56.

Rose PG, Bundy BN, Watkins EB, et al (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med*, 340, 1144-53.

Rosenblatt E, Zubizarreta E (2017). Radiotherapy in cancer care: facing the global challenge, International Atomic Energy Agency Vienna.

Song S, Kim J-Y, Kim Y-J, et al (2013). The size of the metastatic lymph node is an independent prognostic factor for the patients with cervical cancer treated by definitive radiotherapy. *Radiother Oncol*, 108, 168-73.

Wang W, Hou X, Hu K, et al (2019). Which Patients with Cervical Cancer Could Benefit from Prophylactic Extended-Field Irradiation?. *Int J Radiat Oncol Biol Phys*, 105, E339.

Whitney CW, Sause W, Bundy BN, et al (1999). Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. *J Clin Oncol*, 17, 1339.

Yahya S, Bhatt L, King M, et al (2015). Survival and toxicity following chemoradiation for carcinoma of the cervix—impact of multiple-phase treatment and shielding. *Anticancer Res*, 35, 5567-74.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.